Background. Brain metastasis from breast cancer presents a significant threat to women's health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; therefore, we conducted a single-arm phase II trial with these agents. Methods. Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m 2 per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m 2 per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary endpoint was progression-free survival (PFS). Results. Of 25planned patientsthatwould berequiredtodetect a 4-month improvement (from 5 to 9 months) in median PFS with 80% power, 12 were enrolled, and the study was then closed forslow accrual. Median PFS was4.7 months, and median overall survival was 10 months. In the CNS, 25% had progressive disease, and 83% experienced extra-CNS progression. The most common side effects were fatigue and nausea. Conclusion. In 12 evaluable patients studied, concurrent capecitabine and whole-brain radiation followed by capecitabine and sunitinib did not extend PFS over historical rates and was associated with significant toxicity. Our study was small and closed due to slow accrual. The Oncologist 2015;20:13
DISCUSSION
Brain metastasis is one of the most devastating events in breast cancer because it often significantly compromises quality of life and results in rapid death [4] . We sought to improve that with the approach of capecitabine as a radiosensitizer and adding sunitinib later on to target tumor vascularity. Our study was slow to accrue and closed early. Progression-free survival (PFS) in this study of 4.7 months ( Fig. 1) is very similar to the historical PFS of 5 months after whole-brain radiation therapy [15] [16] [17] , leading us to conclude that although the study was underpowered, the study treatment does not show a promising signal for clinical benefit.
Especially in light of its low efficacy, we felt that the treatment toxicity was excessive. Five of the 12 patients (42%) were taken off of the study because of adverse events. Because the study treatment offered little clinical benefit and was associated with significant adverse events, the authors concluded that concurrent capecitabine and sunitinib as treatment for metastatic breast cancer with brain metastases is associated with an unacceptable risk-benefit ratio and cannot be recommended.
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